Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar Adherence Study

European Journal of Heart Failure

Volumn 16, Issue 11, 2014, Pages 1249-1255

  Schou, Morten ^a   Gislason, Gunnar ^a   Videbaek, Lars ^b   Kober, Lars ^c   Tuxen, Christian ^d   Torp Pedersen, Christian ^e   Hildebrandt, Per R ^f   Gustafsson, Finn ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Adherence; Angiotensin converting enzyme inhibitor; Beta blocker; Heart failure clinic; Mineralocorticoid receptor antagonist; Systolic heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; STANDARDS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84916604034     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.176     Document Type: Article

References (21)

1. McAlister FA, Stewart S, Ferrua S, McMurray JJ,. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-819.
2. Clark AM, Savard LA, Thompson DR,. What is the strength of evidence for heart failure disease-management programs? J Am Coll Cardiol 2009; 54: 397-401.
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
4. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van Veldhuisen DJ, Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008; 168: 316-324.
5. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, Sejr Knudsen A, Espersen G, Markenvard J, Egstrup K, Ulriksen H, Hildebrandt PR, NorthStar Investigators, all members of The Danish Heart Failure Clinics Network. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J 2013; 34: 432-442.
6. Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW,. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc 2012; 1: 16-26.
7. Schou M, Gustafsson F, Videbaek L, Markenvard J, Ulriksen H, Ryde H, Jensen JC, Nielsen T, Knudsen AS, Tuxen CD, Handberg J, Sørensen PJ, Espersen G, Lind-Rasmussen S, Keller N, Egstrup K, Nielsen OW, Abdulla J, Nyvad O, Toft J, Hildebrandt PR,. Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics-a randomized Danish multicenter study. Am Heart J 2008; 156: 649-655.
8. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, Rasmussen S, Køber L, Stender S, Madsen M, Torp-Pedersen C,. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153-1158.
9. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sørensen R, Folke F, Gadsbøll N, Rasmussen S, Køber L, Madsen M, Torp-Pedersen C,. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116: 737-744.
10. de la Porte PW, Lok DJ, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NP, Badings E, Hoes AW,. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. Heart 2007; 93: 819-825.
11. Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, Rae B, McMurray JJ, Heart Failure Optimal Outcomes from Pharmacy Study (HOOPS) Investigators. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J 2012; 33: 314-324.
12. van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, Kautzner J, Muñoz Aguilera R, Lunati M, Yu CM, Gerritse B, Borggrefe M, for the DOT-HF Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011; 124: 1719-1726.
13. Schou M, Gustafsson F, Videbaek L, Andersen H, Toft J, Nyvad O, Ryde H, Fog L, Jensen JC, Nielsen OW, Lind-Rasmussen S, Abdulla J, Hildebrandt PR, NorthStar Investigators. Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study). Eur J Heart Fail 2013; 15: 818-827.
14. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, Stroupe KT, Wu J, Clark D, Smith F, Gradus-Pizlo I, Weinberger M, Brater DC,. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 2007; 146: 714-725.
15. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO, Hodshon BV, Cooper LS, Krumholz HM,. Telemonitoring in patients with heart failure. N Engl J Med 2010; 363: 2301-2309.
16. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F,. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34: 2453-2463.
17. Gjesing A, Schou M, Torp-Pedersen C, Køber L, Gustafsson F, Hildebrandt P, Videbæk L, Wiggers H, Demant M, Charlot M, Gislason GH,. Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail 2013; 15: 671-678.
18. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P,. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
19. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS, CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377: 658-666.
20. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008; 168: 847-854.
21. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH,. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359: 1009-1017.